Success Metrics

Clinical Success Rate
75.0%

Based on 3 completed trials

Completion Rate
75%(3/4)
Active Trials
3(43%)
Results Posted
100%(3 trials)
Terminated
1(14%)

Phase Distribution

Ph phase_2
6
86%
Ph phase_1
1
14%

Phase Distribution

1

Early Stage

6

Mid Stage

0

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
1(14.3%)
Phase 2Efficacy & side effects
6(85.7%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

75.0%

3 of 4 finished

Non-Completion Rate

25.0%

1 ended early

Currently Active

3

trials recruiting

Total Trials

7

all time

Status Distribution
Active(3)
Completed(3)
Terminated(1)

Detailed Status

Recruiting3
Completed3
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
7
Active
3
Success Rate
75.0%
Most Advanced
Phase 2

Trials by Phase

Phase 11 (14.3%)
Phase 26 (85.7%)

Trials by Status

recruiting343%
completed343%
terminated114%

Recent Activity

3 active trials
Showing 5 of 7
recruitingphase_2

T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer

NCT02133196
recruitingphase_2

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer

NCT01174121
recruitingphase_2

A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab

NCT02621021
completedphase_2

Prospective Randomized Study of Cell Transfer Therapy for Metastatic Melanoma Using Tumor Infiltrating Lymphocytes Plus IL-2 Following Non-Myeloablative Lymphocyte Depleting Chemo Regimen Alone or in Conjunction With 12Gy Total Body Irradiation (TBI...

NCT01319565
completedphase_2

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma

NCT01993719
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT02133196Phase 2

T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer

Recruiting
NCT01174121Phase 2

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer

Recruiting
NCT02621021Phase 2

A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab

Recruiting
NCT01319565Phase 2

Prospective Randomized Study of Cell Transfer Therapy for Metastatic Melanoma Using Tumor Infiltrating Lymphocytes Plus IL-2 Following Non-Myeloablative Lymphocyte Depleting Chemo Regimen Alone or in Conjunction With 12Gy Total Body Irradiation (TBI...

Completed
NCT01993719Phase 2

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma

Completed
NCT01585415Phase 1

Vemurafenib and White Blood Cell Therapy for Advanced Melanoma

Terminated
NCT01585428Phase 2

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Human Papillomavirus-Associated Cancers

Completed

All 7 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
7